Literature DB >> 22819042

Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the nlrp3 protein.

Yuumi Nakamura1, Luigi Franchi, Naotomo Kambe, Guangxun Meng, Warren Strober, Gabriel Núñez.   

Abstract

Cryopyrin-associated periodic syndromes (CAPS) are caused by aberrant interleukin-1β (IL-1β) production induced by mutations in the NLRP3 protein in humans, but the mechanisms involved remain poorly understood. Using a mouse model, we show a role for the indigenous microbiota and mast cells (MCs) in skin disease associated with mutant Nlrp3 protein. Unlike normal cells, MCs expressing mutant Nlrp3 produced IL-1β in response to lipopolysaccharide or tumor necrosis factor-α (TNF-α). In neonatal mice, the microbiota induced TNF-α and IL-1β and promoted skin disease. MC deficiency greatly reduced disease in Nlrp3 mutant mice, and reconstitution of MC-deficient mice with mutant MCs restored skin disease, which required the expression of IL-1β in MCs. Surprisingly, neutralization of TNF-α abrogated IL-1β production and skin disease in neonatal Nlrp3 mutant mice, but not in affected adult mice. Thus, the microbiota and MCs initiate cellular events leading to dysregulated IL-1β production and skin inflammation in neonatal mice with the CAPS-associated Nlrp3 mutation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819042      PMCID: PMC3411177          DOI: 10.1016/j.immuni.2012.04.013

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  46 in total

1.  Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice.

Authors:  Jae Jin Chae; Young-Hun Cho; Geun-Shik Lee; Jun Cheng; P Paul Liu; Lionel Feigenbaum; Stephen I Katz; Daniel L Kastner
Journal:  Immunity       Date:  2011-05-19       Impact factor: 31.745

2.  A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents.

Authors:  Tomoyo Matsubara; Masanari Hasegawa; Masahiro Shiraishi; Hal M Hoffman; Takashi Ichiyama; Takeo Tanaka; Haruo Ueda; Tokuhiro Ishihara; Susumu Furukawa
Journal:  Arthritis Rheum       Date:  2006-07

3.  Skin mast cells control T cell-dependent host defense in Leishmania major infections.

Authors:  Marcus Maurer; Susanna Lopez Kostka; Frank Siebenhaar; Katharina Moelle; Martin Metz; Jürgen Knop; Esther von Stebut
Journal:  FASEB J       Date:  2006-12       Impact factor: 5.191

4.  The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide.

Authors:  T Kallinich; H M Hoffman; J Roth; R Keitzer
Journal:  Scand J Rheumatol       Date:  2005 May-Jun       Impact factor: 3.641

5.  The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production.

Authors:  Jae Jin Chae; Geryl Wood; Seth L Masters; Katharina Richard; Grace Park; Brian J Smith; Daniel L Kastner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-19       Impact factor: 11.205

6.  Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo.

Authors:  Michele A Grimbaldeston; Ching-Cheng Chen; Adrian M Piliponsky; Mindy Tsai; See-Ying Tam; Stephen J Galli
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

7.  Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice.

Authors:  H Matsuda; N Watanabe; G P Geba; J Sperl; M Tsudzuki; J Hiroi; M Matsumoto; H Ushio; S Saito; P W Askenase; C Ra
Journal:  Int Immunol       Date:  1997-03       Impact factor: 4.823

8.  Mast cell-associated TNF promotes dendritic cell migration.

Authors:  Hajime Suto; Susumu Nakae; Maki Kakurai; Jonathon D Sedgwick; Mindy Tsai; Stephen J Galli
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

9.  The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.

Authors:  Ivona Aksentijevich; Christopher D Putnam; Hal M Hoffman; Daniel L Kastner; Elaine F Remmers; James L Mueller; Julie Le; Richard D Kolodner; Zachary Moak; Michael Chuang; Frances Austin; Raphaela Goldbach-Mansky
Journal:  Arthritis Rheum       Date:  2007-04

10.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Authors:  Raphaela Goldbach-Mansky; Natalie J Dailey; Scott W Canna; Ana Gelabert; Janet Jones; Benjamin I Rubin; H Jeffrey Kim; Carmen Brewer; Christopher Zalewski; Edythe Wiggs; Suvimol Hill; Maria L Turner; Barbara I Karp; Ivona Aksentijevich; Frank Pucino; Scott R Penzak; Margje H Haverkamp; Leonard Stein; Barbara S Adams; Terry L Moore; Robert C Fuhlbrigge; Bracha Shaham; James N Jarvis; Kathleen O'Neil; Richard K Vehe; Laurie O Beitz; Gregory Gardner; William P Hannan; Robert W Warren; William Horn; Joe L Cole; Scott M Paul; Philip N Hawkins; Tuyet Hang Pham; Christopher Snyder; Robert A Wesley; Steven C Hoffmann; Steven M Holland; John A Butman; Daniel L Kastner
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

View more
  41 in total

Review 1.  Mast cell plasticity and sphingosine-1-phosphate in immunity, inflammation and cancer.

Authors:  Carole A Oskeritzian
Journal:  Mol Immunol       Date:  2014-04-22       Impact factor: 4.407

2.  Editorial: Can GPR43 Sensing of Short-Chain Fatty Acids Unchain Inflammasome-Driven Arthritis?

Authors:  Alexander Haslberger; Robert Terkeltaub
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

3.  Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin.

Authors:  Alexandra Taracanova; Irene Tsilioni; Pio Conti; Errol R Norwitz; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-19       Impact factor: 11.205

4.  Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes.

Authors:  Balaji Banoth; Fayyaz S Sutterwala
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

5.  The inflammasomes in autoinflammatory diseases with skin involvement.

Authors:  Hans-Dietmar Beer; Emmanuel Contassot; Lars E French
Journal:  J Invest Dermatol       Date:  2014-03-06       Impact factor: 8.551

6.  Transcription factor GATA1 is dispensable for mast cell differentiation in adult mice.

Authors:  Kinuko Ohneda; Takashi Moriguchi; Shin'ya Ohmori; Yasushi Ishijima; Hironori Satoh; Sjaak Philipsen; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2014-03-10       Impact factor: 4.272

Review 7.  Mast cells as sources of cytokines, chemokines, and growth factors.

Authors:  Kaori Mukai; Mindy Tsai; Hirohisa Saito; Stephen J Galli
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

8.  Mast cells mediate malignant pleural effusion formation.

Authors:  Anastasios D Giannou; Antonia Marazioti; Magda Spella; Nikolaos I Kanellakis; Hara Apostolopoulou; Ioannis Psallidas; Zeljko M Prijovich; Malamati Vreka; Dimitra E Zazara; Ioannis Lilis; Vassilios Papaleonidopoulos; Chrysoula A Kairi; Alexandra L Patmanidi; Ioanna Giopanou; Nikolitsa Spiropoulou; Vaggelis Harokopos; Vassilis Aidinis; Dionisios Spyratos; Stamatia Teliousi; Helen Papadaki; Stavros Taraviras; Linda A Snyder; Oliver Eickelberg; Dimitrios Kardamakis; Yoichiro Iwakura; Thorsten B Feyerabend; Hans-Reimer Rodewald; Ioannis Kalomenidis; Timothy S Blackwell; Theodora Agalioti; Georgios T Stathopoulos
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

Review 9.  Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease.

Authors:  Anthony J St Leger; Rachel R Caspi
Journal:  Bioessays       Date:  2018-10-05       Impact factor: 4.345

Review 10.  Regulation of allergic inflammation by the ectoenzyme E-NPP3 (CD203c) on basophils and mast cells.

Authors:  Shih Han Tsai; Kiyoshi Takeda
Journal:  Semin Immunopathol       Date:  2016-04-30       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.